Effect estimates for the association of BMI and gender, BMI and serum creatinine on PFS, OS and DCB outcomes by anti-PD1 monotherapy and combination (ipilimumab plus nivolumab)
| Outcome: PFS | |
| Type of checkpoint inhibition | Effect Estimatea: HR (95% CI) |
| Anti-PD1 Monotherapy (N = 77) | |
| BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females) | 0.567 (0.233–1.378) |
| BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Males) | 0.509 (0.196–1.323) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 0.439 (0.184–1.047) |
| Ipilimumab plus Nivolumab (N = 59) | |
| BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females) | 0.424 (0.151–1.192) |
| BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Males) | 0.243 (0.093–0.632) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 0.316 (0.120–0.835) |
| Outcome: OS | |
| Type of checkpoint inhibition | Effect Estimate: HR (95% CI) |
| Anti-PD1 Monotherapy (N = 77) | |
| BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females) | 0.331 (0.121–0.903) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 0.208 (0.073–0.591) |
| Ipilimumab plus Nivolumab (N = 59) | |
| BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females) | 0.294 (0.078–1.098) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 0.208 (0.056–0.768) |
| Outcome: DCB | |
| Type of checkpoint inhibition | Effect Estimate: OR (95%CI) |
| Anti-PD1 Monotherapy (N = 75) | |
| BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females) | 5.115 (0.914–28.640) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 7.22 (1.268–41.143) |
| Ipilimumab plus Nivolumab (N = 57) | |
| BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females) | 2.407 (0.456–12.720) |
| BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL) | 2.813 (0.627–12.611) |
aAll effect estimates are un-adjusted